[Traditional and translational medicine].
In the second half of the 20th century, the development of experimental pharmacology led to the discovery of powerful new therapeutic agents, but production has since faltered, particularly in Europe. The purpose of this paper is to review how the gap in the production of novel medicines between Europe and the USA could be filled by proper use of molecular biology data. The European program entitled 'The Innovative Medicines Initiative' could facilitate the translation of information from benchtop to bedside.
Godfraind
Théophile
T
Laboratoire de Pharmacologie, Université catholique de Louvain, Avenue Hippocrate 54, UCL 5410 B1200 Bruxelles.
D015415:Biomarkers; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D004341:Drug Evaluation / Q000639:trends; D005060:Europe; D049672:History, 19th Century; D049673:History, 20th Century; D049690:History, Ancient; D006801:Humans; D008519:Medicine, Traditional / Q000266:history; D008967:Molecular Biology; D010597:Pharmacogenetics; D010601:Pharmacology, Clinical / Q000266:history; D040901:Proteomics; D013678:Technology, Pharmaceutical; D035703:Therapies, Investigational; D014116:Toxicology / Q000379:methods*; D014481:United States
D015415:Biomarkers